| 2026-09-11 17:00 |
8-K |
["5.02"] |
officer change |
0.52
|
CFO departure with severance tied to funding milestones and sale event acceleration; suggests financial restructuring or transaction planning. |
SEC · detail |
| 2026-08-03 16:15 |
8-K |
["3.03", "5.03", "9.01"] |
other |
0.15
|
Certificate of Designation amendment removing 60-day notice requirement for beneficial ownership limitation change; no M&A indicators. |
SEC · detail |
| 2026-07-20 16:15 |
8-K |
["5.07"] |
other |
0.05
|
Routine annual meeting voting results on director election, stock plans, and financing arrangements. No M&A indicators present. |
SEC · detail |
| 2026-07-17 16:05 |
8-K |
["3.03", "5.03", "9.01"] |
other |
0.15
|
Amendment to Series C preferred stock beneficial ownership limit from 4.99% to 9.99%; routine corporate governance change unrelated to M&A. |
SEC · detail |
| 2026-07-02 16:05 |
8-K |
["8.01"] |
other |
0.05
|
Annual meeting adjournment for Nasdaq listing review; no M&A signal. |
SEC · detail |
| 2026-06-18 08:00 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine investor presentation disclosure; no M&A signals present. |
SEC · detail |
| 2026-06-03 08:08 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Routine clinical trial progress announcement; no M&A signals present. |
SEC · detail |
| 2026-06-01 08:59 |
8-K |
["5.08"] |
other |
0.05
|
Routine 8-K announcing 2026 annual meeting date and shareholder proposal deadlines. No M&A signals. |
SEC · detail |
| 2026-05-26 06:43 |
8-K |
["3.01"] |
other |
0.05
|
Nasdaq delisting notice due to insufficient stockholders' equity; seeking shareholder approval to convert preferred stock for compliance. |
SEC · detail |
| 2026-05-22 16:15 |
8-K |
["3.01"] |
other |
0.05
|
Nasdaq delisting notice for stockholders' equity deficiency; no M&A signal. |
SEC · detail |